Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population‐Based Cohort Study
暂无分享,去创建一个
C. Cooper | A. Díez-Pérez | R. Eastell | P. Vestergaard | N. Arden | A. Judge | B. Abrahamsen | D. Prieto-Alhambra | S. Hawley | C. Cooper | K. Rubin | M. Javaid | Bo | Abrahamsen | M. K. Javaid
[1] P. Vestergaard,et al. Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective , 2015, Osteoporosis International.
[2] I. Chiodini,et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis , 2014, Osteoporosis International.
[3] C. Cooper,et al. Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population‐Based Cohort Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] A. LaCroix,et al. Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW) , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] C. Cooper,et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.
[6] K. Olsen,et al. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases , 2013, Osteoporosis International.
[7] C. Cooper,et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) , 2013, Current medical research and opinion.
[8] S. Cummings,et al. Treatment failure in osteoporosis , 2012, Osteoporosis International.
[9] C. Inderjeeth,et al. Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments , 2012, Journal of Bone and Mineral Metabolism.
[10] A. Díez-Pérez,et al. “Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study” , 2012, BMC Musculoskeletal Disorders.
[11] A. Díez-Pérez,et al. Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[13] R. Eastell,et al. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study , 2012, Osteoporosis International.
[14] R. Eastell,et al. Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.
[15] O. Ström,et al. The societal burden of poor persistence to treatment of osteoporosis in Sweden. , 2011, Bone.
[16] Daniel Prieto-Alhambra,et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.
[17] M. Saito,et al. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus , 2010, Osteoporosis International.
[18] J. LeLorier,et al. Differences in persistence among different weekly oral bisphosphonate medications , 2009, Osteoporosis International.
[19] A. Boskey,et al. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women , 2009, Osteoporosis International.
[20] S. Adami,et al. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study , 2008, Osteoporosis International.
[21] Anuja Roy,et al. Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[23] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[24] S. Adami,et al. Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] O. Johnell,et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.
[26] C. Cooper,et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). , 2006, QJM : monthly journal of the Association of Physicians.
[27] B. Ettinger,et al. Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.
[28] Krista F. Huybrechts,et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.
[29] Y. Hundrup,et al. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register , 2004, Scandinavian journal of public health.
[30] Jacques P. Brown,et al. What predicts early fracture or bone loss on bisphosphonate therapy? , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[31] Dieter Felsenberg,et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. , 2003, The Journal of clinical endocrinology and metabolism.
[32] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[33] M. Hochberg,et al. Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial , 2002, Journal of the American Geriatrics Society.
[34] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[35] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[36] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[37] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.